

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ticagrelor

INITIATION

Prerequisites (tick box where appropriate)

- ☐ Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned

INITIATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient has had a neurological stenting procedure* in the last 60 days
or
☐ Patient is about to have a neurological stenting procedure performed*

and

- ☐ Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor

or

- ☐ Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event
or
☐ Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

CONTINUATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient is continuing to benefit from treatment
and
☐ Treatment continues to be clinically appropriate

INITIATION – Percutaneous coronary intervention with stent deployment

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient has undergone percutaneous coronary intervention
and
☐ Patient has had a stent deployed in the previous 4 weeks
and
☐ Patient is clopidogrel-allergic**

INITIATION – Stent thrombosis

Prerequisites (tick box where appropriate)

- ☐ Patient has experienced cardiac stent thrombosis whilst on clopidogrel

INITIATION – Myocardial infarction

Re-assessment required after 1 week

Prerequisites (tick box where appropriate)

- ☐ For short term use while in hospital following ST-elevated myocardial infarction

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ticagrelor - *continued*

Note: Indications marked with * are unapproved indications.
Note: Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

I confirm that the above details are correct:

Signed: Date: